CBX-13 / Cybrexa Therap - LARVOL DELTA

[VIRTUAL] Development of alphalex™-toxin low pH targeting conjugates for the treatment of solid tumors (AACR-II 2020) - "To date Trastuzumab-DM1 (Kadcyla®) remains the only approved antibody-maytansinoid conjugate on the market. In particular we have demonstrated that CBX-13 safely delivers amounts of maytansinoid in vivo that otherwise result in systemic toxicity and death when dosed as free warhead. Based on the SAR of this first generation of maytansinoid conjugates we are further optimizing our alphalexTM - maytansinoid conjugation strategy with the goal of moving forward with IND-enabling studies in the near future."

Oncology • Solid Tumor • HER-2